Viewing
|Articles|August 11, 2008

Cystoid macular oedema drug begins testing

IBI-20089, a drug candidate for the treatment of cystoid macular oedema (CME), has completed patient enrollment for initial clinical testing, according to the drug's manufacturer, Icon Bioscience Inc (IBI).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe

Latest CME